Eli Lilly

  • Capgemini wins Lilly outsourcing contract

    Capgemini announces a £30m outsourcing contract to support and transform the IT infrastructure at pharmaceutical giants Eli Lilly, reinforcing an emerging trend that has seen companies outsource IT resources as a means of slashing costs.
  • TCS starts new facility for Eli Lilly

    TCS announced it has established a relationship with Eli Lilly to advance the pharma's clinical research and development.
  • PETA demands explanation on Lilly's animal outsourcing shift

    Pharmaceutical company Eli Lilly, has been asked to justify its decision to outsource its animal testing to countries with no or poor animal welfare standards, which go against Lilly's commitment to reducing, refining, and replacing its use of animals.
  • Piramal announces Drug Development deal

    Nicholas Piramal and Eli Lilly have signed a landmark new drug development agreement to develop and, in certain regions, commercialize a select group of Lilly’s pre-clinical drug candidates that span multiple therapeutic areas.
  • Galapagos extends Lilly deal

    Galapagos has announced a one year extension of one of its current service contracts with Eli Lilly, said to be worth over €1m.
  • Eli Lilly signals vigour for outsourcing

    Eli Lilly is the latest big pharma company to signal plans of a vigorous commitment to outsourcing in a bid to prevent its fortunes fading.
  • NPIL and Lilly form 'risk and reward' sharing alliance

    Nicholas Piramal (NPIL) has signed an innovative drug development deal with Eli Lilly - the second such agreement in a year.
  • Eli Lilly seeks out Indian firm for second CNS partnership

    Eli Lilly has again teamed up with Indian research firm Suven Life Sciences in a deal that will focus on preclinical research of molecules in the therapeutic area of central nervous system (CNS) disorders.
  • Lilly forges multi million dollar supply chain deal

    BioConvergence has forged a 'significant' supply chain partnership with Eli Lilly, worth millions of dollars over ten years.
  • Lilly sells R&D campus to Covance in pioneering deal

    Eli Lilly took a giant leap down the outsourcing road yesterday with the sale of a major R&D facility to contract research organisation Covance.
  • Eli Lilly outsources work to Quintiles

    Quintiles will perform clinical trials monitoring for Eli Lilly in the US and Puerto Rico as part of a restructuring for Lilly’s research and development operations.
  • i3 assumes bulk of Lilly's US data management

    i3 announced today that Eli Lilly is transferring the majority of its US data management work to i3 Statprobe as part of Lilly’s ongoing effort to transform its business.
  • Lilly and Jubilant team up in drug development JV

    Mere weeks after signing major strategic collaborations with contract service firms Covance, Quintiles and 3i, Eli Lilly has journeyed further down the outsourcing route – albeit with a different spin – by forging another agreement with India’s Jubilant Organosys.
  • Icon secures data management deal with Lilly

    Eli Lilly has continued its march down the outsourcing route and signed a wide-ranging deal with Ireland’s Icon plc in the area of data management.
  • Lilly seals cardiovascular R&D deal with Zydus

    Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.
  • ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe

    ICON announced that it has signed a strategic partnership with Eli Lilly to manage the company’s clinical trial site set up and monitoring in Europe for Lilly managed studies.
  • Lilly sells Tippecanoe API site to Evonik

    US drugmaker Eli Lilly will sell its Tippecanoe laboratories API manufacturing unit to Germany’s Evonik Industries.
  • ICON Selected by Lilly to Oversee its Clinical Data Management in Japan

    ICON signed an extension to its strategic agreement with Eli Lilly to manage the company’s clinical data management outside the US.
  • Jubilant and Lilly Extend Drug Discovery Collaboration

    Jubilant Organosys announced that its 4 year old research collaboration with Eli Lilly has successfully delivered multiple discovery milestones and preclinical candidates, resulting in a five-year extension and an expanded portfolio collaboration.
  • Eli Lilly outsources desktops, webs and messaging to HP

    Eli Lilly has outsourced its global computing and messaging processing to HP Enterprise Services under a seven-year infrastructure services agreement, the companies have said.
  • Covance’s R&D partnership with Lilly expands

    Covance will provide US drug major Eli Lilly with bioproduct analytical testing services under an expansion of the firms’ year-old R&D collaboration.
  • Thermo takes over trial supply production at Lilly Indy plant

    Thermo Fisher Scientific will take charge of clinical trial material production at Eli Lilly’s research technology facility in Indianapolis as the pharmaceutical firm further reduces in-house capacity to cut costs.